To The Moon

As of Tuesday's market close, $Dow Jones(.DJI)$ edged up 1.43%, $S&P 500(.SPX)$rose about 0.91%, and $NASDAQ(.IXIC)$ gained 0.67%, showed bullish performance. Data from TradingView shows that 29 companies with a market cap of over $20 billion have reached new highs.

• Rate Cut Expectations Increase: With weaker economic data (such as retail sales and producer prices), coupled with dovish comments from several Federal Reserve officials, expectations for a rate cut in December rose sharply, boosting investor sentiment.

• Bond Yields Fall & U.S. Dollar Weakens: U.S. long-term bond yields declined, and the dollar weakened against major currencies, which supported stock markets, particularly growth and small-cap stocks.

• Tech/AI Sector Volatility: While AI and chip stocks remained a key focus, the sector showed volatility as increasing competition (such as concerns around Nvidia and AMD) and uncertainty about business prospects for some companies dampened sentiment in the tech space.

According to TradingView, on Tuesday, there were 29 stocks with market value over $20B that saw prices hit all time high. Below are the TOP 10 stocks with analyst rating of buy and ranked by market value: $Alphabet(GOOG)$ $Broadcom(AVGO)$ $Eli Lilly(LLY)$ $Johnson & Johnson(JNJ)$ $TJX Companies(TJX)$ $Hca Healthcare Inc(HCA)$ $McKesson(MCK)$ $Nu Holdings Ltd.(NU)$ $Monster Beverage(MNST)$ $Cencora Inc.(COR)$

Looking at the specific data analysis:

• 9 companies with EPS dil growth rate over 30%: $Travelers(TRV)$ $Alphabet(GOOG)$ $Nu Holdings Ltd.(NU)$ $Hilton(HLT)$ $STERIS plc(STE)$ $McKesson(MCK)$ $Johnson & Johnson(JNJ)$ $Eli Lilly(LLY)$ $Broadcom(AVGO)$

• 5 companies with negative EPS growth: $Insmed(INSM)$ $Natera(NTRA)$ $Cincinnati(CINF)$ $Steel Dynamics(STLD)$ $General Motors(GM)$ $Loews(L)$

• 1 company without EPS dil growth rate provided: $Viking Holdings Ltd.(VIK)$

The following is a compilation of key drivers behind the record-high stock prices of the top 10 companies, based on publicly available information. This is for discussion purposes only.

1. $Alphabet(GOOG)$

• Core Business & Latest Business Developments: Alphabet operates through segments like Google Services, Google Cloud, and Other Bets. It continues to lead in AI with initiatives like AI Max and Gemini, which are driving growth in search ads and cloud services. Recent product launches include AI Overviews and AI Mode, enhancing user experience and increasing query volume.

• Recent Financial Highlights: In Q2 2025, Alphabet reported consolidated revenues of $96.4 billion, up 14% year-over-year. Google Services revenues increased 12% to $82.5 billion, while Google Cloud revenues grew 32% to $13.6 billion. Net income increased 19%, and EPS increased 22% to $2.31. The company plans to increase its 2025 capital expenditures to approximately $85 billion, reflecting its commitment to technical infrastructure expansion. Alphabet also spent $11.5 billion on share buybacks and $2.5 billion on dividends during the quarter.

  

2. $Broadcom(AVGO)$

• Core Business & Latest Business Developments: Broadcom (AVGO) is a global technology leader whose core business spans semiconductor and infrastructure software solutions, with a growing focus on AI-driven data center technologies. The company is a key supplier of custom AI accelerators (XPUs) and high-performance networking chips to hyperscale cloud customers like Google and Meta, and it continues to benefit from the AI infrastructure boom.

• Recent Financial Highlights: In Q3 FY2025, Broadcom reported record revenue of $16 billion, up 22% year-over-year, driven by a 63% surge in AI semiconductor revenue to $5.2 billion. Adjusted EBITDA reached a record $10.7 billion, up 30% YoY, while free cash flow hit $7.0 billion. The company also announced a new $10 billion share repurchase program and returned $2.8 billion to shareholders via dividends. Despite strength in AI, non-AI semiconductor revenue remains sluggish, with a recovery not expected until late 2026.

  

3. $Eli Lilly(LLY)$

• Core Business & Latest Business Developments: Eli Lilly is a global pharmaceutical company focused on developing innovative medicines in areas such as diabetes, obesity, oncology, and immunology. Its key products include Mounjaro and Zepbound, which have seen significant growth. The company continues to invest in research and development to expand its pipeline of new drugs.

• Recent Financial Highlights: In Q3 2025, Eli Lilly reported revenue of $17.60 billion, a 54% increase year-over-year. Net income was $5.58 billion, or $6.21 per share. Mounjaro generated $6.52 billion in revenue, up 109% from the same period last year, while Zepbound contributed $3.59 billion, up 184% year-over-year. The company raised its full-year revenue guidance to between $63 billion and $63.5 billion and adjusted profit guidance to between $23 and $23.70 per share.

  

4. $Johnson & Johnson(JNJ)$

• Core Business & Latest Business Developments: Johnson & Johnson is a diversified healthcare company with operations in pharmaceuticals, medical devices, and consumer health. The company continues to focus on innovation and expanding its product portfolio in these segments, including recent advancements in pharmaceuticals and medical devices.

• Recent Financial Highlights: In Q2 2025, Johnson & Johnson reported strong financial results. The company's revenue grew by 12% year-over-year, driven by robust performance across all segments. Pharmaceuticals revenue increased by 15%, medical devices revenue grew by 10%, and consumer health revenue rose by 5%. The company's net income was $4.5 billion, with earnings per share of $1.62. Johnson & Johnson also maintained a strong dividend payout, reflecting its commitment to shareholder returns.

  

5. $TJX Companies(TJX)$

• Core Business & Latest Business Developments: TJX Companies operates as a global retailer of discounted fashion apparel and home goods. The company continues to expand its global presence and enhance its omnichannel retail strategy. Recent highlights include the opening of 13 new stores in the second quarter of FY2026, bringing the total store count to 5,134.

• Recent Financial Highlights: In Q2 2026, TJX reported net sales of $13.5 billion, up 7% year-over-year. Earnings per share were $1.12, exceeding expectations. The company's gross profit margin was 32.3%, up 170 basis points year-over-year. Net cash from operating activities was $4.4 billion, with free cash flow of $2.0 billion.

  

6. $Hca Healthcare Inc(HCA)$

• Core Business & Latest Business Developments: HCA Healthcare (HCA) operates one of the largest networks of hospitals and outpatient care facilities in the United States, providing acute care, surgical services, emergency care, and specialized clinical services. The company emphasizes expansion of inpatient and outpatient capacity, increased surgical volumes, and integrated care delivery across its hospitals, surgery centers, and urgent-care sites.

• Recent Financial Highlights: HCA reported strong momentum in its latest results, with Q3 2025 revenue increasing about 9.6% to over $19 billion, driven by higher surgical procedures and outpatient activity. Net income rose approximately 29%, resulting in a ~43% increase in diluted EPS, while adjusted EBITDA grew around 18%, reflecting improved operational leverage and cost management.

  

7. $McKesson(MCK)$

• Core Business & Latest Business Developments: McKesson (MCK) is a dominant U.S. pharmaceutical distributor—one of the “Big 3” wholesalers—whose core business is sourcing and delivering branded, generic, and specialty drugs to retail pharmacies, health systems, and mail-order clients, augmented by medical-surgical supplies and prescription-technology services.

• Recent Financial Highlights: Fiscal 2025 (ended Mar-25) revenue rose 16 % to $359 billion and adjusted EPS jumped to $25.86; FY-26 guidance was lifted twice, most recently to $38.35-$38.85 after Q2 results. In the first half of FY-26 alone the company returned $1.6 billion to shareholders ($1.4 billion in buy-backs plus $179 million in dividends) while still growing adjusted operating profit 13 % in North American Pharma and 71 % in the Oncology & Multi-specialty segment.

  

8. $Nu Holdings Ltd.(NU)$

• Core Business & Latest Business Developments: Latin America’s largest digital-only bank now serves 127 million customers across Brazil, Mexico and Colombia with no-fee credit cards, unsecured & secured loans, savings, insurance and crypto trading, all delivered through a single mobile app. Management is executing an “AI-first” pivot: embedding large-language models to create hyper-personalised offers, real-time spending insights and AI-driven collections, while internally using generative AI to sharpen underwriting and fraud detection.

• Recent Financial Highlights: Q3 2025 results show the scalability of the model: revenue hit a record $4.2 billion, up 39 % YoY (FX-neutral), net income rose 39 % to $783 million and annualised ROE reached a record 31 %. Gross profit grew 32 % to $1.8 billion and margin expanded 130 bp QoQ to 43.5 %, while the monthly cost-to-serve stayed below $1 per active customer. Total deposits climbed 34 % YoY to $38.8 billion, funding a 42 % surge in the credit portfolio to $30.4 billion; the 15-90-day NPL ratio improved 20 bp QoQ to 4.2 %, underscoring stable asset quality amid rapid growth.

  

9. $Monster Beverage(MNST)$

• Core Business & Latest Business Developments: Monster is the global leader in energy drinks, marketing brands such as Monster Energy®, Reign®, Bang® and affordable Strategic Brands acquired from Coca-Cola. The company drives growth through relentless flavour innovation, zero-sugar line extensions, larger single-serve cans that carry higher dollar margins, and aggressive international roll-outs; management is also pushing into alcohol-based “hard” energy and functional beverages to widen demographic reach .

• Recent Financial Highlights: Q3 2025 delivered across both volume and profitability: net sales rose 16.8 % to a record $2.20 billion, with the core Monster Energy® segment up 17.7 % to $2.03 billion. Operating income jumped 40.7 % to $675 million, net income increased 41.4 % to $525 million and diluted EPS grew 41 % to $0.53, beating consensus by more than 10 %.

  

10. $Cencora Inc.(COR)$

• Core Business & Latest Business Developments: Cencora Inc., formerly AmerisourceBergen, is one of the world’s largest pharmaceutical distributors, sourcing and delivering branded, generic and specialty drugs plus related services to U.S. retail pharmacies, health systems, physician practice,s and specialty clinics through its U.S. Healthcare Solutions segment (~90 % of revenue).

• Recent Financial Highlights: In Q3 2025 rose 9.3 % to a record $321.3 billion, gross profit climbed 15.8 % to $11.5 billion and GAAP diluted EPS advanced to $7.96. In the final quarter revenue grew 8.7 % YoY to $80.7 billion while adjusted diluted EPS jumped 19.8 % to $4.00; the U.S. segment’s operating income surged 29 %, more than offsetting a 13 % decline internationally. The board recently lifted FY-26 EPS guidance and declared a $0.55 quarterly dividend, continuing a shareholder-friendly capital-allocation stance.

  

Conclusion

The record-high stock prices of these ten companies on November 25th, 2025. Major companies across sectors showed strong growth driven by AI, pharmaceuticals, and consumer demand. Alphabet saw a 14% YoY revenue increase to $96.4 billion, with significant growth in Google Cloud and AI. Broadcom posted a 22% revenue increase, driven by AI semiconductors, while Eli Lilly reported a 54% revenue surge, primarily from Mounjaro and Zepbound. Johnson & Johnson saw a 12% revenue growth, and TJX exceeded expectations with a 7% YoY sales increase. HCA Healthcare benefited from higher surgical procedures, while McKesson grew 16% YoY, and Nu Holdings reported a 39% rise in revenue. Monster Beverage saw record sales, and Cencora posted a 9.3% revenue increase, alongside strong U.S. operating income growth. These results reflect broad-based strength across technology, healthcare, retail, and diagnostics sectors, fueled by innovation, AI adoption, and resilient consumer demand.

Call to Action

We invite you to explore these companies further and consider their potential impact on your investment portfolio or business strategy.

Join the conversation and share your insights on these market leaders. What do you think will be the next big trend driving their growth? Let us know in the comments below.

For SG users only, A tool to boost your purchasing power and trading ideas with CashBoost!

For whom haven't open CBA can know more from below:

🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!

Complete your first Cash Boost Account trade with a trade amount of ≥ SGD 5000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.

Click to access the activity

Other helpful links:

• 💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉

• How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.